Viyash Scientific Limited — Investor Meet, 22-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Viyash Scientific Limited held an earnings conference call to discuss the financial results for Q4 and the full year FY26. The company reported a strong Q4 FY26 with revenue at ₹920 Cr, a 19.1% YoY increase. Full-year revenue grew 13.8% to ₹3,420 Cr. Adjusted EBITDA saw a significant jump, up 59.6% to ₹702 Cr for the full year, with margins expanding by 590 basis points to 20.5%. PAT turned around significantly, reaching ₹225 Cr for FY26 compared to ₹16 Cr in FY25.

Management highlighted the successful integration of the business into a unified platform, strengthening execution and operating leverage. The company is evaluating selective inorganic opportunities alongside organic growth for FY27. Key focus areas include product pipeline expansion, R&D acceleration, and manufacturing upgrades in animal and human health formulations. The API and CDMO business is showing strong momentum, with potential for significant future growth. The company expressed confidence in its growth roadmap, deleveraged balance sheet, and ability to create long-term value. The overall sentiment is positive and forward-looking.